Has Novavax Successfully Pivoted Its Business Model

Opendoor's resale velocity increased and inventory levels tightened, signaling potential early traction for the company's "Opendoor 2.0" strategic reset. These operational improvements suggest the fir...

The COVID-19 vaccine boom rapidly generated fortunes for three companies, but the subsequent market shift suggests only one firm possesses a viable long-term strategy.

Novavax achieved Q4 profitability by shifting to a royalty-driven model, with 73% of revenue from licensing and royalties. FY26 revenue guidance is set at $230M–$270M, excluding potential Sanofi miles...